Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 4.325
Filter
1.
Rev. otorrinolaringol. cir. cabeza cuello ; 82(3): 303-310, sept. 2022. ilus, tab
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1409938

ABSTRACT

Resumen Introducción: El personal de otorrinolaringología presenta una elevada exposición al virus SARS-CoV-2, debido a los procedimientos que lleva a cabo. Es fundamental tomar las medidas de protección adecuadas. Determinar la seroprevalencia nos dará un mejor panorama sobre la exposición, contagios y efectividad de medidas de protección adoptadas. Objetivo: Determinar la prevalencia de resultados serológicos positivos en personal médico que presta servicio en la Cátedra de Otorrinolaringología de marzo del 2020 a marzo de 2021. Material y Método: Estudio observacional, descriptivo, corte transversal, retrospectivo con asociación cruzada. Muestreo no probabilístico de casos consecutivos. La población total fue de 38 médicos del Servicio de Otorrinolaringología del Hospital de Clínicas. Resultados: La media de edades fue 37,4 años, 63,5% refirió haber atendido a paciente conocido portador de COVID-19. Un 42% refirió no haber cumplido con todas las medidas de protección personal, mientras que un 23,7% de los sujetos de estudio dio positivo para IgG, interpretándose como infección previa por COVID-19. Conclusión: Más de las dos terceras partes de los médicos refirió dar consulta a paciente COVID-19 positivo. Casi la cuarta parte de los médicos resultó ser positivo para COVID-19 según la prueba de serología anti-N. No se halló asociación entre consulta ni cirugía a pacientes portadores de COVID-19 y el contagio al personal médico.


Abstract Introduction: Otolaryngology personnel have a high exposure to SARS-CoV-2 virus due to the procedures they perform. It is essential to take appropriate protective measures. Determining seroprevalence will give us a better picture of exposure, contagion and effectiveness of protective measures adopted. Aim: To determine the prevalence of positive serological results in medical staff serving in the otolaryngology department from March 2020 to March 2021. Material and Method: Observational, descriptive, cross-sectional, retrospective, retrospective study with cross-association. Non-probability sampling of consecutive cases. The total population was 38 physicians of the Otolaryngology Service of the Hospital de Clinicas. Results: The mean age was 37.4. 63.5% reported having seen a patient known to be a COVID-19 carrier, while 42% reported not having complied with all personal protection measures. A 23.68% of the study subjects tested positive for IgG, interpreting previous COVID-19 infection. Conclusion: More than two-thirds of the physicians referred to giving consultation to COVID-19 positive patients. Almost a quarter of the physicians were positive for COVID-19 according to the Anti-N serology test. No association was found between consultation or surgery of patients with COVID-19 and infection of medical personnel.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Immunoglobulin G/analysis , Immunoglobulin M/analysis , Seroepidemiologic Studies , Health Personnel/statistics & numerical data , Otolaryngologists/statistics & numerical data , COVID-19/immunology , Paraguay/epidemiology , Security Measures , Prevalence , Retrospective Studies , Personal Protection , COVID-19 Serological Testing , SARS-CoV-2/immunology
2.
s.l; CONETEC; 2 jul. 2022.
Non-conventional in Spanish | LILACS, BRISA | ID: biblio-1379533

ABSTRACT

INTRODUCCIÓN: El sotrovimab está disponible en presentación de 500 mg/8 ml (62,5 mg/ml). La Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, su sigla del inglés Food and Drug Administration) de los Estados Unidos autorizó en 2021 el uso de sotrovimab para el tratamiento de COVID-19 de leve a moderado en adultos, y ciertos pacientes pediátricos con resultados positivos de pruebas virales directas de SARS-CoV-2, y que tienen un alto riesgo de progresión a COVID-19 grave, incluidos hospitalización o muerte. La institución recomienda que debe ser administrado por un proveedor de atención médica calificado como una infusión intravenosa única tan pronto como sea posible después de la prueba viral positiva para COVID-19 y dentro de los siete días posteriores al inicio de los síntomas. (13) La Agencia Europea de Medicamentos (EMA, su sigla del inglés European Medicines Agency), en cambio, la ha autorizado en 2021 para el tratamiento de la COVID-19 en adultos y adolescentes (a partir de 12 años y con un peso mínimo de 40 kg) que no necesitan oxígeno suplementario y que tienen un mayor riesgo de que la enfermedad se agrave. OBJETIVO: El objetivo del presente informe es evaluar parámetros de eficacia, seguridad, conveniencia y recomendaciones disponibles acerca del empleo de sotrovimab para el tratamiento de pacientes con COVID-19 en Argentina. MÉTODOS: Efectos en la Salud: Teniendo en cuenta la velocidad con la que la información relacionada a la pandemia aparece y se modifica, se desarrolló un protocolo sustentado en proyectos que resume activamente la evidencia científica a medida que la misma se hace disponible. Implementación Este dominio contempla dos subdominios: la existencia de barreras y facilitadores en nuestro contexto para la implementación de la tecnología evaluada no consideradas en los otros dominios analizados, y los costos comparativos en relación con otras intervenciones similares. Con el objetivo de emitir un juicio de valor sobre la magnitud de dichos costos, en pacientes hospitalizados se utilizó como comparador al tratamiento con dexametasona, que ha demostrado ser una intervención accesible y de beneficios importantes en el contexto analizado. Recomendaciones: Para la identificación de recomendaciones sustentadas en evidencia y actualizadas, se utilizó la plataforma COVID recmap. RESULTADOS: Se identificaron dos revisiones sistemáticas que cumplieron con los criterios de inclusión del presente informe. Se identificaron tres ECA que incluyeron 4934 pacientes con COVID-19, en los que se administró sotrovimab en comparación con el mejor estándar de atención. CONCLUSIONES: El cuerpo de la evidencia muestra que existe incertidumbre en el efecto de sotrovimab sobre la mortalidad y la necesidad de ventilación mecánica (certeza muy baja ⨁◯◯◯). Sotrovimab probablemente reduzca las hospitalizaciones en pacientes con enfermedad leve de reciente comienzo y factores de riesgo para progresión a enfermedad severa. Sin embargo, la magnitud de la reducción solo resulta importante (mayor a 1%) para pacientes sin esquema de vacunación completo o con riesgo de respuesta inmune inapropiada. La tecnología no está autorizada para su comercialización por la Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) de nuestro país al momento de la fecha de realización del presente informe. Asimismo, su costo estimado es elevado y tendría un gran impacto presupuestario si se tiene en cuenta la elevada población objetivo a ser tratada. Las guías de práctica clínica de alta calidad metodológica actualizadas sugieren a favor de usar sotrovimab en pacientes con alto riesgo de hospitalización, no vacunados y con factores de riesgo (edad e inmunocomprometidos) teniendo en cuenta las variables circulantes en la región, dado que no resulta efectivo frente a la variante Omicron.


Subject(s)
Humans , SARS-CoV-2/drug effects , COVID-19/drug therapy , Immunoglobulin G/therapeutic use , Efficacy , Cost-Benefit Analysis
3.
Rev. argent. reumatolg. (En línea) ; 33(2): 83-89, abr. - jun. 2022. ilus
Article in Spanish | LILACS, BINACIS | ID: biblio-1393394

ABSTRACT

Introducción: la enfermedad relacionada con IgG4 (ER-IgG4) es una afección inmunomediada, asociada con lesiones fibroinflamatorias que pueden ocurrir en casi cualquier órgano. Ante su sospecha clínica es fundamental realizar el examen histopatológico para excluir malignidad y otras enfermedades. El objetivo principal de este estudio fue describir los hallazgos histológicos de la biopsia de glándulas salivales labiales (GSL) en pacientes con diagnóstico de ER-IgG4 y, posteriormente, comparar estos hallazgos con la histología e inmunohistoquímica de la glándula salival mayor (GSM). Materiales y métodos: estudio retrospectivo, observacional y descriptivo sobre una cohorte de 40 pacientes con diagnóstico de ER-IgG4. Se incluyeron 26 pacientes con diagnóstico de ER-IgG4 que presentaron biopsias de GSL. Resultados: el 73% de la muestra tuvo un infiltrado linfoplasmocitario y el 11%, fibrosis con patrón no estoriforme. En ningún caso se halló arteritis obliterativa ni ninguna forma de flebitis. Al realizar la comparación con los hallazgos de las biopsias de GSM, no hubo significancia estadística. El 65% de los pacientes manifestó compromiso extraglandular y fueron los sistemas pancreato hepato biliar y las adenopatías los más afectados. Conclusiones: la biopsia incisional de glándula submandibular sería más útil y apropiada que la biopsia de GSL para un diagnóstico definitivo de ER-IgG4.


Introduction: IgG4-related disease (IgG4-RD) is an immune-mediated condition associated with fibroinflammatory lesions that can occur in almost any anatomical site. Histopathological examination is essential when suspected to diagnose it to exclude malignancy and other diseases. The objective of this study was to describe the histological findings of the minor salivary gland biopsy (GSL) in patients diagnosed with IgG4-RD, and subsequently to correlate these findings with the histology and immunohistochemistry of the major salivary gland (GSM). Materials and methods: retrospective, observational and descriptive study on a cohort of 40 patients diagnosed with RD-IgG4. Twenty-six patients diagnosed with IgG4-RD who presented SLG biopsies were included. Results: the 73% of the samples presented a lymphoplasmacytic infiltrate and 11% of them fibrosis with a non-storiform pattern. In no case was obliterative arteritis or any form of phlebitis found. When comparing the findings of the GSM biopsies, there was no statistical significance. Sixty-five percent of the patients presented extraglandular involvement; the pancreato-hepato-biliary system and the adenopathies were the most affected. Conclusions: incisional biopsy of the submandibular gland would be more useful and appropriate than LSG for a definitive diagnosis of IgG4-RD.


Subject(s)
Immunoglobulin G , Salivary Glands , Biopsy
4.
Lima; Instituto Nacional de Salud; abr. 2022.
Non-conventional in Spanish | LILACS, BRISA | ID: biblio-1369447

ABSTRACT

ANTECEDENTES: Este informe se efectúa en atención a la solicitud de la Dirección General de Intervenciones Estratégicas de Salud Pública del Ministerio de Salud. El objetivo es sintetizar la evidencia científica publicada respecto a la eficacia y seguridad de Sotrovimab en el tratamiento de pacientes con COVID-19. MÉTODOS: Pregunta PICO abordada: En pacientes adultos con COVID-19 ¿la administración de Sotrovimab es eficaz y seguro en comparación a no administrarlo? Criterios de elegibilidad: Los criterios de selección de los estudios fueron los siguientes: Revisiones sistemáticas de ensayos clínicos aleatorizados: Ensayos clínicos aleatorizados (ECA) que reporten resultados para al menos uno de los desenlaces. Ensayos clínicos que hayan evaluado Sotrovimab en combinación con otros anticuerpos monoclonales. Estudios publicados en idioma inglés y español. Se excluyeron cartas al editor, revisiones narrativas, estudios preclínicos (estudios in vitro o en modelos animales) y artículos de opinión. Métodos para la búsqueda e identificación de la evidencia: Para la identificación de las revisiones sistemáticas se efectuó una búsqueda manual en la plataforma de COVID-END disponible en https://www.mcmasterforum.org/networks/covid-end, recuperándose dos revisiones sistemáticas vivas: Revisión sistemática del Consorcio COVID-NMA(1) disponible en https://covid-nma.com/ actualizada al 16 de marzo de 2022, disponible en https://covid- nma.com/living_data/index.php?treatment1=Sotrovimab&submit=Validate#comparisons_div Revisión Rápida de la Organización Panamericana de la Salud (OPS) (2), versión del 15 de marzo de 2022, disponible en https://iris.paho.org/handle/10665.2/52719 Para recuperar ensayos clínicos aleatorizados que no hubieran sido incluidos en las revisiones antes señaladas, se efectuó una búsqueda manual en la Plataforma Living Overview of the Evidence (L·OVE) de la Fundación Epistemonikos. Se realizó además una búsqueda en las páginas web oficiales de agencias reguladoras de Medicamentos como la Food and Drug Administration (FDA) de Estados Unidos, la Agencia Europea de Medicamentos (EMA) y la Dirección General de Medicamentos, Insumos y Drogas (DIGEMID) de Perú. RESULTADOS: Sotrovimab es un anticuerpo monoclonal IgG1 humanizado producido mediante tecnología de ADN recombinante. Se une a un epítopo altamente conservado en el dominio de unión al receptor (RBD) de la proteína S o espiga del SARS-CoV-2 y con ello evita la unión del SARS-CoV-2 mediada por esta proteína y la entrada en las células humanas. CONCLUSIONES: Sotrovimab es un anticuerpo monoclonal IgG1 humanizado que une a un epítopo altamente conservado en el dominio de unión al receptor (RBD) de la proteína S del SARS-CoV-2 y con ello evita la unión del virus mediada por esta proteína y la entrada a las células humanas. Ha sido autorizado por la FDA de Estados Unidos y la EMA para el tratamiento de COVID-19 en personas ≥ 12 años, con COVID-19 leve a moderado no hospitalizados, que no requieren oxígeno suplementario y que tienen un mayor riesgo de progresar a COVID-19 severo. El objetivo del informe fue sintetizar la evidencia científica respecto a la eficacia y seguridad de Sotrovimab en el tratamiento de pacientes con COVID-19. Se identificaron 2 ensayos clínicos aleatorizados realizados previo a la aparición de variantes del SARS-CoV-2 como la delta y ómicron. La evidencia proporcionada por estos corresponde a población no vacunada. Evidencia de 1 ensayo clínico (pre-print) en pacientes no hospitalizados, con COVID-19 leve a moderado, tiempo de enfermedad ≤ 5 días y con factores de riesgo para progresión a enfermedad severa. Evidencia de 1 ensayo clínico en pacientes con COVID-19 moderado a severo, hospitalizados, sin oxígeno o con oxigenoterapia convencional, y con tiempo de enfermedad ≤ 12 días. Estudios in vitro mostraron que la capacidad de neutralización de Sotrovimab se mantuvo frente a la variante Ómicron (B.1.1.529 y BA.1), a excepción del sublinaje BA.2, donde su capacidad se vio seriamente afectada (4 estudios). Sin embargo, no es posible predecir la eficacia clínica a partir de estos datos.


Subject(s)
Humans , Immunoglobulin G/therapeutic use , SARS-CoV-2/drug effects , COVID-19/drug therapy , Efficacy , Cost-Benefit Analysis
5.
Lima; Instituto Nacional de Salud; feb. 2022.
Non-conventional in Spanish | LILACS, BRISA | ID: biblio-1369684

ABSTRACT

ANTECEDENTES: Este informe se efectúa en atención a la solicitud de la Dirección General de Intervenciones Estratégicas de Salud Pública del Ministerio de Salud. El objetivo es sintetizar la evidencia científica publicada respecto a la eficacia y seguridad de Sotrovimab en el tratamiento de pacientes con COVID-19. ANÁLISIS: MÉTODOS: Pregunta PICO abordada: En pacientes adultos con COVID-19 ¿la administración de Sotrovimab es eficaz y seguro en comparación a no administrarlo? Criterios de elegibilidad: Los criterios de selección de los estudios fueron los siguientes: Revisiones sistemáticas de ensayos clínicos aleatorizados. Ensayos clínicos aleatorizados (ECA) que reporten resultados para al menos uno de los desenlaces. Ensayos clínicos que hayan evaluado Sotrovimab en combinación con otros anticuerpos monoclonales. Estudios publicados en idioma inglés y español. Se excluyeron cartas al editor, revisiones narrativas, estudios preclínicos (estudios in vitro o en modelos animales) y artículos de opinión. Métodos para la búsqueda e identificación de la evidencia: Para la identificación de las revisiones sistemáticas se efectuó una búsqueda manual en la plataforma de COVID-END(1), recuperándose dos revisiones sistemáticas vivas: Revisión sistemática del Consorcio COVID-NMA(2) disponible en https://covid-nma.com/ actualizada al 04 de febrero de 2022. Revisión Rápida de la Organización Panamericana de la Salud (OPS)(3), versión del 26 de enero de 2022, disponible en https://iris.paho.org/handle/10665.2/52719 RESULTADOS: Sotrovimab es un anticuerpo monoclonal IgG1 humanizado producido mediante tecnología de ADN recombinante. Se une a un epítopo altamente conservado en el dominio de unión al receptor (RBD) de la proteína S o espiga del SARS-CoV-2 y con ello evita la unión del SARS-CoV-2 mediada por esta proteína y la entrada en las células humanas. CONCLUSIONES: Sotrovimab es un anticuerpo monoclonal IgG1 humanizado que une a un epítopo altamente conservado en el dominio de unión al receptor (RBD) de la proteína S del SARS-CoV-2 y con ello evita la unión del virus mediada por esta proteína y la entrada a las células humanas. Ha sido autorizado por la FDA de Estados Unidos y la EMA para el tratamiento de COVID-19 en personas ≥ 12 años, con COVID-19 leve a moderado no hospitalizados, que no requieren oxígeno suplementario y que tienen un mayor riesgo de progresar a COVID-19 severo. El objetivo del informe fue sintetizar la evidencia científica respecto a la eficacia y seguridad de Sotrovimab en el tratamiento de pacientes con COVID-19. Se identificaron 2 ensayos clínicos aleatorizados realizados previo a la aparición de variantes del SARS-CoV-2 como la delta y ómicron. La evidencia proporcionada por estos corresponde a población no vacunada. Evidencia de 1 ensayo clínico (pre-print) en pacientes no hospitalizados, con COVID-19 leve a moderado, tiempo de enfermedad ≤ 5 días y con factores de riesgo para progresión a enfermedad severa mostró lo siguiente: Sotrovimab en comparación a no administrarlo podría tener poco o ningún impacto sobre la mortalidad a los 28 días: 1 de cada 1000 participantes tratados con Sotrovimab murieron en comparación con 4 de cada 1000 personas que recibieron placebo; RR 0.20; IC 95%: 0.01 a 4.16; 1 ECA, 1057 participantes; certeza baja. La evaluación a los 60 días mostró un resultado similar. Sotrovimab podría tener poco o ningún impacto sobre la necesidad de ventilación mecánica invasiva (VMI) los 28 días: 1 de cada 1000 participantes tratados con Sotrovimab requirieron VMI en comparación con 8 de cada 1000 personas que recibieron placebo; RR 0.11; IC 95%: 0.01 a 2.06; 1 ECA, 1057 participantes; certeza baja. Sotrovimab probablemente reduce la necesidad de hospitalización o la muerte por cualquier causa: 11 de cada 1000 participantes tratados con Sotrovimab fueron hospitalizados o murieron en comparación con 57 de cada 1000 personas que recibieron placebo; RR 0.20; IC 95%: 0.08 a 0.48; 1 ECA, 1057 participantes, certeza moderada. Sotrovimab probablemente reduce la incidencia de eventos adversos serios en comparación con No administrarlo: 21 de cada 1000 participantes reportaron algún evento adverso serio en comparación a 60 de cada 1000; RR 0.34; IC 95%: 0.18 a 0.68; 1 ECA, 1057 participantes; certeza moderada. Evidencia de 1 ensayo clínico en pacientes con COVID-19 moderado a severo, hospitalizados, sin oxígeno o con oxigenoterapia convencional, y con tiempo de enfermedad ≤ 12 días señaló que: Sotrovimab en comparación a no administrarlo probablemente no tiene ningún impacto sobre la mortalidad evaluada a los 28 días y a los 90 días. 1 ECA, 367 participantes; certeza moderada. Sotrovimab en comparación a no administrarlo podría tener poco o ningún impacto sobre la progresión a ventilación mecánica invasiva o la muerte a los 28 días. 1 ECA, 367 participantes; certeza baja. Sotrovimab en comparación a no administrarlo, probablemente no origina un incremento de la incidencia de eventos adversos serios; 1 ECA, 367 participantes; evidencia de certeza moderada. Estudios in vitro mostraron que la capacidad de neutralización de Sotrovimab se mantuvo frente a la variante Ómicron, a excepción del sublinaje BA.2, donde su capacidad se vio seriamente afectada. Sin embargo, no es posible predecir la eficacia clínica a partir de estos datos.


Subject(s)
Humans , Immunoglobulin G/therapeutic use , SARS-CoV-2/drug effects , COVID-19/drug therapy , Efficacy , Cost-Benefit Analysis
6.
Rev. saúde pública (Online) ; 56: 1-8, 2022. tab
Article in English | LILACS, BBO | ID: biblio-1377229

ABSTRACT

ABSTRACT OBJECTIVE To estimate the prevalence of hepatitis A virus (HAV) and hepatitis E virus (HEV) among immigrants and refugees in Goiás, Central Brazil. METHODS Overall, 355 individuals were interviewed, and blood samples were tested for anti-HAV and anti-HEV IgG. Anti-HEV-positive samples were similarly tested for HEV RNA. RESULTS All participants were from Latin American countries, most of whom, young adult males. The overall anti-HAV IgG prevalence was 87.4% (95%CI: 83.5-90.4), of whom 94.9%, 75.6%, and 60% were from Haiti, Venezuela, and other Latin American countries, respectively (p < 0.001). Age above 19 years and more than 36 months residing in Brazil were associated with a higher prevalence of previous HAV and HEV infection, respectively. Of the children eligible for HAV vaccination according to the National Immunization Program, only eight (44%) had been vaccinated. The overall anti-HEV IgG prevalence was 6.5% (95%CI: 4.4-9.5). All anti-HEV IgG-positive individuals were Haitians, including a child born in Brazil. HEV RNA was detected in two of the anti-HEV IgG-positive samples. CONCLUSION The survey detected a high prevalence of anti-HAV and anti-HEV IgG among immigrants and refugees, and active HEV infection among some Haitian participants. Prevention measures are urgently required to interrupt enteric virus transmission in this emergent and vulnerable population.


Subject(s)
Humans , Male , Child , Adult , Young Adult , Refugees , Hepatitis E virus/genetics , Hepatitis E/epidemiology , Hepatitis A virus/genetics , Emigrants and Immigrants , Hepatitis A/epidemiology , Brazil/epidemiology , Immunoglobulin G , RNA , Hepatitis Antibodies , Hepatitis A Antibodies , Haiti
7.
Cad. Saúde Pública (Online) ; 38(4): ES219821, 2022. tab, graf
Article in Spanish | LILACS | ID: biblio-1374816

ABSTRACT

Los estudios seroepidemiológicos permiten conocer la distribución indirecta de las enfermedades, detectando marcadores séricos de inmunidad y demostrando infecciones no diagnosticadas en la población general. El objetivo fue estimar la seroprevalencia de anticuerpos contra el SARS-CoV-2, en Córdoba, Argentina, entre diciembre de 2020 y enero de 2021, e identificar factores asociados a la contagiosidad del virus. Se realizó un estudio observacional transversal, de base poblacional, con 3.225 individuos mayores de 2 años, residentes en Córdoba Capital, que fueron seleccionados mediante un diseño de muestreo aleatorio en múltiples etapas, proporcional a la distribución por género, franja etaria y nivel socioeconómico de la población de Córdoba. Las características clínicas, antropometría y comorbilidades se recogieron mediante entrevistas. Se realizó un test serológico cualitativo para la detección de anticuerpos IgG antinucleocápside para SARS-CoV-2 (ARCHITECT, Abbott). La seroprevalencia del SARS-CoV-2 se estimó en la población y por franja de edad, sexo, nivel socioeconómico y presencia de las patologías estudiadas. Las razones de prevalencia (RP) se estimaron usando un modelo de regresión log-binomial. La seropositividad para SARS-CoV-2 fue de 16,68% (IC95%: 15,41-18,01). Tener entre 2 y 18 años, residir en barrios con nivel socioeconómico bajo y la presencia de obesidad, aumentaron la oportunidad de seropositividad (RP = 1,50; IC95%: 1,10-2,04, RP = 1,91; IC95%: 1,34-2,67 y RP = 1,39; IC95%: 1,04-1,85). Los resultados indican que en Córdoba Capital existen atributos diferenciales que aumentan la posibilidad de ser seropositivo para SARS-CoV-2. Esto permite dirigir estrategias de vigilancia epidemiológica para reducir la propagación del virus.


Seroepidemiological studies help identify the indirect distribution of diseases, detecting serological markers of immunity and demonstrating undiagnosed infections in the general population. The objectives were to estimate the seroprevalence of SARS-CoV-2 antibodies in Córdoba, Argentina, from December 2020 to January 2021 and to identify factors associated with the virus' contagiousness. A population-based cross-sectional observational study was performed in 3,225 individuals over two years of age living in Córdoba city, selected by multiple-stage random sampling proportional to distribution by gender, age group, and socioeconomic status in the city's population. Clinical characteristics, anthropometry, and comorbidities were collected by interview. Qualitative serological testing was performed for detection of SARS-CoV-2 nucleocapsid IgG antibodies (ARCHITECT, Abbott). SARS-CoV-2 seroprevalence was estimated for the total population and by age group, sex, socioeconomic status, and presence of target diseases. Prevalence ratios (PR) were estimated using a log-binomial regression model. SARS-CoV-2 seropositivity was 16.68% (95%CI: 15.41-18.01). Age 2 to 18 years, living in neighborhoods with low socioeconomic status, and obesity increased the odds of seropositivity (PR = 1.50; 95%CI: 1.10-2.04, PR = 1.91; 95%CI: 1.34-2.67 and PR = 1.39; 95%CI: 1.04-1.85). The results indicate that the city of Córdoba displays differential attributes that increase the likelihood of a positive SARS-CoV-2 antibody test. This allows targeting epidemiological surveillance strategies to reduce the spread of the virus.


Os estudos soroepidemiológicos permitem conhecer a distribuição indireta das doenças, detectando marcadores séricos de imunidade e demonstrando infecções não diagnosticadas na população geral. O objetivo foi estimar a soroprevalência de anticorpos contra o SARS-CoV-2, em Córdoba, Argentina, entre dezembro de 2020 e janeiro de 2021, e identificar fatores associados à contagiosidade do vírus. Um estudo observacional transversal foi realizado, de base populacional, com 3.225 indivíduos maiores de 2 anos, residentes em Córdoba Capital, que foram selecionados por meio de um delineamento de amostragem aleatória em múltiplos estágios, proporcional à distribuição de gênero, a faixa etária e o nível socioeconômico da população de Córdoba. As características clínicas, antropometria e comorbidades foram coletadas por meio de entrevistas. Um teste sorológico qualitativo foi realizado para a detecção de anticorpos IgG anti-nucleocapsídeo para SARS-CoV-2 (ARCHITECT, Abbott). A soroprevalência do SARS-CoV-2 foi estimada na população e por faixa etária, sexo, nível socioeconômico e presença das patologias estudadas. Razões de prevalência (RP) foram estimadas usando um modelo de regressão log-binomial. A soropositividade para SARS-CoV-2 foi de 16,68% (IC95%: 15,41-18,01). Ter entre 2 e 18 años, residir em bairros com nível socioeconômico baixo e a presença de obesidade aumentaram a chance de soropositividade (RP = 1,50; IC95%: 1,10-2,04, RP = 1,91; IC95%: 1,34-2,67 e RP = 1,39; IC95%: 1,04-1,85). Os resultados indicam que em Córdoba Capital existem atributos diferenciais que aumentam a possibilidade de ser soropositivo para SARS-CoV-2. Isso permite direcionar estratégias de vigilância epidemiológica para reduzir a propagação do vírus.


Subject(s)
Humans , Child, Preschool , Child , Adolescent , COVID-19/epidemiology , Argentina/epidemiology , Brazil , Immunoglobulin G , Seroepidemiologic Studies , Cross-Sectional Studies , SARS-CoV-2 , Antibodies, Viral
8.
Article in English | WPRIM | ID: wpr-928976

ABSTRACT

OBJECTIVES@#With the continuous generation of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pressure of epidemic prevention and control continues to increase in China. Omicron with stronger infectiousness, immune escape ability and repeated infection ability spread to many countries and regions around the world in a short period of time. China has also successively reported cases of imported Omicron infections. This study aims to understand the epidemiological characteristics of Omicron variant via analyzing the epidemiological characteristics of imported patients with Omicron in Hunan Province, and to provide reference for preventing and controlling the imported epidemics.@*METHODS@#The clinical data of imported patients with coronavirus disease 2019 admitted to Hunan Province from December 16 to December 31, 2021 were retrospectively collected. The epidemiological information, general information, clinical classification, clinical symptoms, vaccination status, and lung CT were analyzed. Nasopharyngeal swabs and blood samples were collected. Virus nucleic acid was detected by magnetic beads method using SARS-CoV-2 detection kit. Ct values of ORF1ab gene and N gene were compared between asymptomatic infected patients and confirmed patients. The specific IgM and IgG antibodies were detected by chemiluminescence assay using SARS-CoV-2 IgM test kit and SARS-CoV-2 IgG test kit, respectively. Ct values of IgM and IgG antibodies were compared between asymptomatic infected patients and confirmed patients.@*RESULTS@#Seventeen patients with Omicron variant infection were treated in Hunan, including 15 confirmed patients (5 common type and 10 mild type) and 2 asymptomatic infection patients. The 17 patients were all Chinese, they were generally young, and 16 were male. There were 9 patients with diseases. Of them 3 patients had respiratory diseases. All 17 patients had completed the whole process of vaccination, but only one person received a booster shot of SARS-CoV-2 vaccine. The clinical manifestations of the patients were mild, mainly including dry/painful/itchy throat, cough, and fatigue. The total protein and creatine in the asymptomatic infection and confirmed cases infected with Omicron variant were all within the normal range, but other biochemical indicators were abnormal. There were the significant differences in C-reactive protein and fibrinogen between asymptomatic infection and confirmed patients (both P<0.05). There were more patients with elevated C-reactive protein in confirmed patients than without confirmed ones. The detection rate of specific IgM and IgG antibodies on admission was 100%, and there was no significant difference in the specific antibody levels between asymptomatic infection and confirmed patients (P>0.05). There were no significant differences in Ct values of ORF1ab gene and N gene (21.35 and 18.39 vs 19.22 and 15.67) between the asymptomatic infection and the confirmed patients (both P>0.05). Only 3 patients had abnormal lung CT, showing a small amount of patchy and cord-like shadows. One of them had no abnormality on admission but had pulmonary lesions and migratory phenomenon after admission.@*CONCLUSIONS@#The patients with Omicron variant tend to be young people and have milder clinical symptoms, but the viral load is high and the infectiveness is strong. Therefore, the timely identification and effective isolation and control for asymptomatic infections and confirmed patients with mild symptoms are extremely important. In terms of epidemic prevention and control, the government still needs to strengthen the risk control of overseas input, adhere to normalized epidemic prevention and control measures, to effectively control the source of infection, cut off the route of transmission, and protect vulnerable people.


Subject(s)
Asymptomatic Infections , C-Reactive Protein , COVID-19/virology , COVID-19 Vaccines , China/epidemiology , Female , Humans , Immunoglobulin G , Immunoglobulin M , Male , Retrospective Studies , SARS-CoV-2
9.
Frontiers of Medicine ; (4): 378-388, 2022.
Article in English | WPRIM | ID: wpr-939871

ABSTRACT

Macrolide and corticosteroid resistance has been reported in patients with Mycoplasma pneumoniae (MP) pneumonia (MPP). MP clearance is difficult to achieve through antibiotic treatment in sensitive patients with severe MPP (SMPP). SMPP in children might progress to airway remodeling and even bronchiolitis/bronchitis obliterans. Therefore, identifying serum biomarkers that indicate MPP progression and exploring new targeted drugs for SMPP treatment require urgency. In this study, serum samples were collected from patients with general MPP (GMPP) and SMPP to conduct proteomics profiling. The Fc fragment of the IgG-binding protein (FCGBP) was identified as the most promising indicator of SMPP. Biological enrichment analysis indicated uncontrolled inflammation in SMPP. ELISA results proved that the FCGBP level in patients with SMPP was substantially higher than that in patients with GMPP. Furthermore, the FCGBP levels showed a decreasing trend in patients with GMPP but the opposite trend in patients with SMPP during disease progression. Connectivity map analyses identified 25 possible targeted drugs for SMPP treatment. Among them, a mechanistic target of rapamycin kinase (mTOR) inhibitor, which is a macrolide compound and a cell proliferation inhibitor, was the most promising candidate for targeting SMPP. To our knowledge, this study was the first proteomics-based characterization of patients with SMPP and GMPP.


Subject(s)
Biomarkers , Carrier Proteins , Child , Humans , Immunoglobulin Fc Fragments , Immunoglobulin G , Macrolides , Mycoplasma pneumoniae , Pneumonia, Mycoplasma/drug therapy , Proteomics
10.
Article in English | WPRIM | ID: wpr-939848

ABSTRACT

Immunoglobulin G4-related sialadenitis (IgG4-RS) is an immune-mediated fibro-inflammatory disease and the pathogenesis is still not fully understood. The aim of this study was to explore the role and mechanism of interleukin-13 (IL-13) in the cellular senescence during the progress of IgG4-RS. We found that the expression of IL-13 and IL-13 receptor α1 (IL-13Rα1) as well as the number of senescent cells were significantly higher in the submandibular glands (SMGs) of IgG4-RS patients. IL-13 directly induced senescence as shown by the elevated activity of senescence-associated β-galactosidase (SA-β-gal), the decreased cell proliferation, and the upregulation of senescence markers (p53 and p16) and senescence-associated secretory phenotype (SASP) factors (IL-1β and IL-6) in SMG-C6 cells. Mechanistically, IL-13 increased the level of phosphorylated signal transducer and activator of transcription 6 (p-STAT6) and mitochondrial-reactive oxygen species (mtROS), while decreased the mitochondrial membrane potential, ATP level, and the expression and activity of superoxide dismutase 2 (SOD2). Notably, the IL-13-induced cellular senescence and mitochondrial dysfunction could be inhibited by pretreatment with either STAT6 inhibitor AS1517499 or mitochondria-targeted ROS scavenger MitoTEMPO. Moreover, IL-13 increased the interaction between p-STAT6 and cAMP-response element binding protein (CREB)-binding protein (CBP) and decreased the transcriptional activity of CREB on SOD2. Taken together, our findings revealed a critical role of IL-13 in the induction of salivary gland epithelial cell senescence through the elevated mitochondrial oxidative stress in a STAT6-CREB-SOD2-dependent pathway in IgG4-RS.


Subject(s)
Cellular Senescence/genetics , Humans , Immunoglobulin G/metabolism , Interleukin-13/pharmacology , Mitochondria/metabolism , Sialadenitis/metabolism
11.
Article in Chinese | WPRIM | ID: wpr-939655

ABSTRACT

OBJECTIVES@#To investigate the serum level of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific RBD IgG antibody (SARS-CoV-2 IgG antibody for short) in children with SARS-CoV-2 Omicron variant infection during the recovery stage, as well as the protective effect of SARS-CoV-2 vaccination against Omicron infection.@*METHODS@#A retrospective analysis was performed on 110 children who were diagnosed with coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 Omicron variant infection in Tianjin of China from January 8 to February 7, 2022. According to the status of vaccination before diagnosis, they were divided into a booster vaccination (3 doses) group with 2 children, a complete vaccination (2 doses) group with 90 children, an incomplete vaccination (1 dose) group with 5 children, and a non-vaccination group with 13 children. The clinical data and IgG level were compared among the 4 groups.@*RESULTS@#The complete vaccination group had a significantly higher age than the non-vaccination group at diagnosis (P<0.05), and there was a significant difference in the route of transmission between the two groups (P<0.05). There were no significant differences among the four groups in sex, clinical classification, and re-positive rate of SARS-CoV-2 nucleic acid detection (P>0.05). All 97 children were vaccinated with inactivated vaccine, among whom 85 children (88%) were vaccinated with BBIBP-CorV Sinopharm vaccine (Beijing Institute of Biological Products, Beijing, China). At 1 month after diagnosis, the booster vaccination group and the complete vaccination group had a significantly higher level of SARS-CoV-2 IgG antibody than the non-vaccination group (P<0.05), and at 2 months after diagnosis, the complete vaccination group had a significantly higher level of SARS-CoV-2 IgG antibody than the non-vaccination group (P<0.05). For the complete vaccination group, the level of SARS-CoV-2 IgG antibody at 2 months after diagnosis was significantly lower than that at 1 month after diagnosis (P<0.05).@*CONCLUSIONS@#Vaccination with inactivated SARS-CoV-2 vaccine has a protective effect against Omicron infection in children. For children vaccinated with 2 doses of the vaccine who experience Omicron infection, there may be a slight reduction in the level of SARS-CoV-2 IgG antibody at 2 months after diagnosis. Citation:Chinese Journal of Contemporary Pediatrics, 2022, 24(7): 736-741.


Subject(s)
Antibodies, Viral , COVID-19 , COVID-19 Vaccines , Child , Humans , Immunoglobulin G , Retrospective Studies , SARS-CoV-2 , Viral Vaccines
12.
Article in Chinese | WPRIM | ID: wpr-936106

ABSTRACT

Some kinds of chronic sialadenitis were recognized during the recent years. They have specific pathogenesis, clinical and histopathologic appearances, and require specific treatment. IgG4-related sialadenitis (IgG4-RS) is one of the immune-mediated diseases, characterized by tumefactive lesions. The incidence of IgG4-RS obviously increased during the past 30 years. The study on the potential relationship between occupational exposure to chemical substances and the incidence of IgG4-RS showed that subjects with occupational exposure to agents known to cause IgG4-RD had an increased risk for IgG4-RS. Surgical excision of involved SMG could not control the disease progression, which is not recommended for treatment of IgG4-RS. The combination of glucocorticoid and steroid-sparing agents is effective for treating IgG4-RS, and restores salivary gland function. Radioiodine induced sialadenitis (RAIS) is one of the common complications of postoperative adjuvant treatment of differentiated thyroid cancer by 131I. The incidence of the disease is related to radiation dosage. Clinically, the patients suffered from swelling and tenderness in the buccal or submandibular regions, especially during the mealtime. Imaging appearances are similar to those of chronic obstructive sialadenitis. Conservative managements, such as gland massage, sialagogues, are the mainstream methods in the treatment of RAIS. Sialendoscopy is feasible for RAIS, but not as effective as conventional obstructive sialadenitis (COS). Therefore the prevention of RAIS is crucial. Eosinophilic sialodochitis (ES) is a new type of chronic inflammatory disease of the salivary gland related to allergy. It has characteristics of swelling of multiple major salivary glands, strip-like gelatinous plugs discharged from the duct orifice of the gland, elevated level of serum IgE and eosinophils in peripheral blood, infiltration of eosinophils and IgE positive plasma cells in the tissues, allergic history, increased expression of allergy-related cytokines, such as IL-4, IL-5, IL-13, and eotaxin, which suggest allergic reactions as a potential pathogenesis of the disease. The clinical, laboratory, histological, and immunohistochemical characteristics of ES are significantly different from conventional obstructive sialadenitis (COS). Therefore, it is suitable to separate ES from COS. Conservative managements, such as self-maintenance therapy and anti- allergic modality are the choices of treatment for ES. Based on the results of our comprehensive studies a new classification of chronic sialadenitis is suggested.


Subject(s)
Humans , Immunoglobulin G , Iodine Radioisotopes , Salivary Glands , Sialadenitis/etiology , Submandibular Gland
13.
Chinese Journal of Hepatology ; (12): 452-456, 2022.
Article in Chinese | WPRIM | ID: wpr-935966

ABSTRACT

IgG4-related disease (IgG4-RD) is an immune-mediated condition associated with chronic fibroinflammatory lesions that can affect nearly any organ. IgG4-related hepatobiliary and pancreatic diseases are IgG4-RD involving the hepatobiliary and pancreatic system, which is characterized with elevated serum IgG4 concentrations, large numbers of IgG4 positive lymphoplasma cells infiltration in affected organs, storiform fibrosis, and imaging changes of organ morphology. Due to the lack of reliable biomarkers, histopathology is still an important basis for diagnosis. The pathogenesis of IgG4-related hepatobiliary and pancreatic diseases has not been clarified. This review focuses on the recent advances in intestinal microecology-immunology, host genetics-immunity and recurrence monitoring of IgG4-related hepatobiliary and pancreatic diseases.


Subject(s)
Autoimmune Diseases/diagnosis , Gastrointestinal Microbiome , Humans , Immunoglobulin G , Immunoglobulin G4-Related Disease/pathology , Pancreatic Diseases
14.
Chinese Journal of Pediatrics ; (12): 329-333, 2022.
Article in Chinese | WPRIM | ID: wpr-935696

ABSTRACT

Objective: To summarize changes of serum immunoglobulin levels before and after chemotherapy in children with Burkitt lymphoma (BL), so as to investigate the effects of chemotherapy and rituximab on serum immunoglobulin levels in children with BL. Methods: Clinical data of 223 children with newly diagnosed Burkitt lymphoma at Beijing Children's Hospital from January 2009 to April 2017 were analyzed retrospectively. They were treated according to the modified LMB 89 regimen and some of them received combined rituximab therapy during the chemotherapy. The serum immunoglobulin (IgA, IgM, IgG) before chemotherapy, at the time of discontinuing chemotherapy, as well as 6, 12, 24, 36 months after chemotherapy were collected. Changes of serum IgA, IgM and IgG with time among different treatment groups were compared using repeated measures ANOVA. Results: According to risk group, 223 children were devided into group B(n=53)and group C(n=170). Before chemotherapy, 109 cases (48.9%) were combined with hypogammaglobulinemia. The serum IgA, IgM, and IgG levels of all the patients were (0.9±0.7), 1.2 (0.5, 1.3) and (7.2±2.9) g/L before chemotherapy, (0.5±0.4), 0.2 (0.1, 0.3) and (6.3±2.3) g/L at the time of discontinuing chemotherapy (t=13.63, Z=-11.99, t=4.57, all P<0.05). There were statistical difference in IgA, IgM levels of group B and IgA, IgM, IgG levels of group C before chemotherapy and at the time of discontinuing chemotherapy (t=8.86, Z=-6.28, t=11.19, Z=-10.15, t=4.50, all P<0.05). The differences of serum IgA and IgG levels at the time after chemotherapy among patients treated with chemotherapy alone and those treated with chemotherapy combined rituximab in group B and C were significant (F=5.38, P=0.002 and F=4.22, P=0.007). Conclusions: Approximately half of children with BL have already existed hypogammaglobulinemia at initial diagnosis prior to the start of treatment. The modified LMB 89 regimen have significant effect on humoral immunity of children with BL. In the process of immune reconstruction after chemotherapy, rituximab has more significant effect on serum IgA and IgG levels in BL patients.


Subject(s)
Agammaglobulinemia , Burkitt Lymphoma/drug therapy , Child , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Immunoglobulin M/blood , Retrospective Studies , Rituximab/therapeutic use
15.
Article in Chinese | WPRIM | ID: wpr-935309

ABSTRACT

Objective: To evaluate the safety and immunogenicity of hepatitis E vaccine(HEV)in Maintenance hemodialysis(MHD)patients. Methods: Based on an open-labeled controlled trial, from May 2016 to March 2018, 35 eligible MHD patients were recruited in the Hemodialysis Center of Zhongshan Hospital Affiliated to Xiamen University as the experimental group, and 70 MHD patients with matched age, gender and underlying diseases as the control group. The experimental group received HEV at 0, 1 and 6 months according to the standard vaccination procedures, while the control group received routine diagnosis and treatment without vaccine and placebo injection to observe the safety and immunogenicity of the vaccine. The safety of vaccine in MHD population was evaluated by the incidence of adverse reactions/events in the experimental and control groups. The immunogenicity of HEV in MHD patients was evaluated by comparing the data from the phase Ⅲ clinical trial. Results: The overall incidence of adverse reactions/events was 17.1% (18/105), and there were no grade 3-4 adverse reactions/events related to vaccination. In the experimental group, the incidence of local adverse reactions/events was 20.0% (7/35), and the incidence of systemic adverse reactions/events was 17.1% (6/35).There was no significant difference in the incidence of systemic adverse reactions/events between the experimental group and the control group (P>0.05). There were 23 patients receiving 3 doses with the standard schedule. The positive rate of HEV-IgG antibody was 100% and the GMC was 14.47(95%CI:13.14-15.80) WU/ml, which showed no significant difference compared with the 46 patients in Phase Ⅲ clinical trial (t=-1.04, P>0.05). Conclusion: Recombinant HEV has good safety and immunogenicity in MHD patients.


Subject(s)
Clinical Trials, Phase III as Topic , Female , Hepatitis E , Humans , Immunogenicity, Vaccine , Immunoglobulin G , Male , Renal Dialysis , Viral Hepatitis Vaccines/adverse effects
16.
Article in Chinese | WPRIM | ID: wpr-935240

ABSTRACT

Objective: To express DNA-binding protein (DBP) of human adenovirus (HAdV) type 7 using the prokaryotic expression system, and product anti-HAdV-7 DBP rabbit polyclonal antibody. Methods: The HAdV-7 DBP gene was synthesized and cloned into prokaryotic expressing vector pET30a, and the recombinant plasmid was transformed into E. coli BL21 (DE3) competent cell. The recombinant protein DBP was expressed by induced Isopropyl-beta-D-thiogalactopyranoside (IPTG) and purified with Ni-NTA affinity column. The titer of anti-DBP polyclonal antibody produced in immunized rabbit was measured by indirect ELISA, and the specificity of the antibody was identified by Western blotting and indirect immunofluorescence assay (IFA). In addition, purified rDBP was used as coating antigen for indirect ELISA assay to detect specific IgM and IgG antibodies against DBP in the serum of children infected with HAdV. Results: The HAdV-7 DBP plasmid was constructed successfully. The purified recombinant DBP was more than 95% after purification. The titer of polyclonal antibody was 1∶1 024 000. The polyclonal antibody showed high specificity in vitro using Western blotting and IFA. The positive rate of specific anti-DBP IgM and IgG antibody in acute-phase serum samples collected from children infected with HAdV were 50.0% (19/38) and 63.2% (24/38), respectively, using indirect ELISA. Conclusion: In summary, the HAdV-7 rDBP is expressed using prokaryotic expression system, and the recombinant HAdV-7 DBP protein and the anti-DBP rabbit polyclonal antibody with high titer are prepared.


Subject(s)
Adenoviruses, Human/genetics , Animals , Antibody Specificity , Blotting, Western , DNA-Binding Proteins/metabolism , Enzyme-Linked Immunosorbent Assay , Escherichia coli/genetics , Immunoglobulin G , Rabbits
17.
Article in Chinese | WPRIM | ID: wpr-928752

ABSTRACT

OBJECTIVE@#To investigate the titer of IgG anti-A/B erythrocyte antibody in vivo of the neonate with hemolytic disease of newborn(HDN), and explore its clinical valua in evaluating the severity of HDN.@*METHODS@#300 neonates with HDN, 50 neonates with neonatal hyperbilirubinemiain and 50 healthy neonates were selected as research object and Microtubes Gel Test was used to detect the titer of IgG anti-A/B erythrocyte antibody in vivo. Their clinical data and their mothers' prenatal examination data were retrospectively analyzed. Three hemolysis tests (direct antiglobulin test, free antibody test and release test), irregular antibody screening, and the titer of IgG anti-A/B blood group antibody was determined by serological method. Red blood cells(RBC), hemoglobin(Hb), reticulocytes(Ret) and nucleated red cells were detected by hematology analyzer. Indirect bilirubin and albumin(Alb) were detected by biochemical analyzer. The relationship between the titer of IgG anti-A/B erythrocyte antibody in vivo and the severity of HDN was analyzed.@*RESULTS@#There were six serological diagnosis modes in the HDN group,the difference between modes was statistically significant (P<0.05). The antibody titer relationship between HDN neonates and pregnant women was positive correlation(r=0.8302). The highest antibody titer of release test and free antibody test were 1∶32 and 1∶2, and the difference was statistically significant(P<0.05). RBC, Hb and Alb in HDN patients were lower than those in neonatal hyperbilirubinemia patients and healthy neonates (P<0.05), and were negatively relevant with antibody titer in vivo (r=-0.8016). Bilirubin content in HDN patients were higher than those in neonatal hyperbiliru binemia patients and healthy neonates group(P<0.05), and was positively relevant with antibody titer in vivo (r=0.8731). The hospital day in HDN patients was significantly relevant with the antibody titer in vivo (r=0.8547), but not with the age, sex, weight and ABO blood types (P>0.05).@*CONCLUSION@#The detection of antibody titer in HDN patients can be used to evaluate the antibody concentration in vivo, predict the ability of antibody to induce erythrocyte hemolysis, and help to judge the serenrity and prognosis of HDN.


Subject(s)
ABO Blood-Group System , Bilirubin , Blood Group Incompatibility , Erythroblastosis, Fetal , Erythrocytes , Female , Hematologic Diseases , Hemolysis , Humans , Immunoglobulin G , Infant, Newborn , Pregnancy , Retrospective Studies
18.
Article in Chinese | WPRIM | ID: wpr-928737

ABSTRACT

OBJECTIVE@#To investigate the expression and clinical significance of miR-424 and miR-765 in patients with multiple myeloma (MM).@*METHODS@#The eighty-one MM patients admitted to Sanya Central Hospital from January 2017 to July 2020 were divided into phase Ⅰ (n=16), phase Ⅱ (n=25) and phase Ⅲ (n=40) according to the international staging system, while they were divided into IgG type (n=46), IgA type (n=19), light chain type (n=10) and non secretory type (n=6) according to the results of immunotyping. Another 50 healthy normal persons in the same period were selected as the control group. The levels of serum miR-424, miR-765 and Cystatin C (Cys-C) were measured in each group. The diagnostic value of serum miR-424, miR-765 and Cys-C in MM was estimated by ROC curve. Pearson correlation was used to analyze the correlation between serum levels of miR-424, miR-765 and Cys-C in MM patients.@*RESULTS@#The serum levels of miR-424 (2.74±1.30 vs 0.85±0.26), miR-765 (2.05±0.82 vs 0.63±0.17) and Cys-C [(2.18±0.86 vs 0.72±0.15) mg/L] in MM group were significantly higher than those in control group (P<0.001). The serum levels of miR-424 (5.08±2.36 vs 1.12±0.34, 2.24±0.93), miR-765 (3.50±1.52 vs 0.74±0.20, 1.78±0.65) and Cys-C [(3.81±1.30 vs 0.92±0.24, 1.68±0.55) mg/L] in MM patients at stage Ⅲ were significantly higher than those in patients at stage Ⅰ and Ⅱ (P<0.001). Also the serum levels of the three molecules in phase II were significantly higher than those in phase I (P<0.001). The serum levels of miR-424 and miR-765 in MM patients at IgG type were significantly higher than those at IgA, light chain and non secretory types (P<0.001). ROC curve analysis showed that the area under the curve (0.952,95%CI: 0.890-0.993) was greatest for the combination of miR-424, miR-765 and Cys-C for diagnosis of MM, and its sensitivity and specificity were 95.0% and 87.2%. The results of correlation analysis showed that the serum levels of miR-424 and miR-765 were positively correlated with Cys-C (r=0.795,r=0.760).@*CONCLUSION@#The serum levels of miR-424 and miR-765 in MM patients are significantly increased in the pattern increasing with the progression of MM stage. Combined with Cys-C, miR-424 and miR-765 have high value in the diagnosis of MM.


Subject(s)
Humans , Immunoglobulin A , Immunoglobulin G , MicroRNAs , Multiple Myeloma , ROC Curve
19.
Article in Chinese | WPRIM | ID: wpr-928702

ABSTRACT

OBJECTIVE@#To establish a based method flow cytometry to identify the antigen Jka in human red blood cells (RBCs) and verify its accuracy.@*METHODS@#A total of 96 blood samples were enrolled in the study randomly from the voluntary blood donors in Shenzhen Blood Center. The RBCs were incubated with IgG anti-Jka primary antibody, and then labeled with the secondary antibody anti-IgG-Alexa Fluor 647. The fluorescence histograms of each sample were obtained by flow cytometry. Serological agglutination test was used to compare the accuracy of flow cytometry in the detecting of antigen Jka, while PCR-SSP and gene sequencing genotyping were used to verify the accuracy of flow cytometry in the detecting of the antigen in human RBCs.@*RESULTS@#The results of flow cytometry for antigen Jka in human RBCs were consistent with those from serological tests. Samples that demonstrated higher serological agglutination intensity also showed higher fluorescence activity, which indicate more stronger of Jka antigen. The sensitivity of flow cytometry was higher than that of serological test; especially in distinguish Jka weak and negative samples. Flow cytometric results of all samples were consistent with the genotyping results, which confirmed the accuracy of flow cytometry.@*CONCLUSION@#The study established a new flow cytometry-based method successfully for the identification of Jka antigen of Kidd blood group in human RBCs. The Kidd blood group antigen Jka of different intensities can be accurately distinguished by the technique.


Subject(s)
Blood Group Antigens , Blood Grouping and Crossmatching , Erythrocytes , Flow Cytometry , Humans , Immunoglobulin G , Kidd Blood-Group System
20.
Chinese Journal of Traumatology ; (6): 138-144, 2022.
Article in English | WPRIM | ID: wpr-928493

ABSTRACT

PURPOSE@#The incidence of acute lung injury (ALI) in severe trauma patients is 48% and the mortality rate following acute respiratory distress syndrome evolved from ALI is up to 68.5%. Alveolar epithelial type 1 cells (AEC1s) and type 2 cells (AEC2s) are the key cells in the repair of injured lungs as well as fetal lung development. Therefore, the purification and culture of AEC1s and AEC2s play an important role in the research of repair and regeneration of lung tissue.@*METHODS@#Sprague-Dawley rats (3-4 weeks, 120-150 g) were purchased for experiment. Dispase and DNase I were jointly used to digest lung tissue to obtain a single-cell suspension of whole lung cells, and then magnetic bead cell sorting was performed to isolate T1α positive cells as AEC1s from the single-cell suspension by using polyclonal rabbit anti-T1a (a specific AEC1s membrane protein) antibodies combined with anti-rabbit IgG microbeads. Afterwards, alveolar epithelial cell membrane marker protein EpCAM was designed as a key label to sort AEC2s from the remaining T1α-neg cells by another positive immunomagnetic selection using monoclonal mouse anti-EpCAM antibodies and anti-mouse IgG microbeads. Cell purity was identified by immunofluorescence staining and flow cytometry.@*RESULTS@#The purity of AEC1s and AEC2s was 88.3% ± 3.8% and 92.6% ± 2.7%, respectively. The cell growth was observed as follows: AEC1s stretched within the 12-16 h, but the cells proliferated slowly; while AEC2s began to stretch after 24 h and proliferated rapidly from the 2nd day and began to differentiate after 3 days.@*CONCLUSION@#AEC1s and AEC2s sorted by this method have high purity and good viability. Therefore, our method provides a new approach for the isolation and culture of AEC1s and AEC2s as well as a new strategy for the research of lung repair and regeneration.


Subject(s)
Alveolar Epithelial Cells/cytology , Animals , Cell Culture Techniques , Cell Separation/methods , Immunoglobulin G/metabolism , Lung , Magnetic Phenomena , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL